INOVIQ LTD.
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non… Read more
INOVIQ LTD. (EGQ0) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, INOVIQ LTD. (EGQ0) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
INOVIQ LTD. - Net Assets Trend (None–None)
This chart illustrates how INOVIQ LTD.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for INOVIQ LTD. (None–None)
The table below shows the annual net assets of INOVIQ LTD. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to INOVIQ LTD.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
INOVIQ LTD. Competitors by Market Cap
The table below lists competitors of INOVIQ LTD. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Foremost Lithium Resource & Technology Ltd. Common stock
NASDAQ:FMST
|
$18.70 Million |
|
Aetherium Acquisition Corp
NASDAQ:GMFI
|
$18.70 Million |
|
Full Circle Lithium Corp.
PINK:FCLIF
|
$18.71 Million |
|
Yuan Jen Enterprises Co Ltd
TW:1725
|
$18.71 Million |
|
Ortoma AB Series B
ST:ORT-B
|
$18.69 Million |
|
INVENTUS MNG CORP.
F:3GIA
|
$18.69 Million |
|
TOP Engineering Co. Ltd
KQ:065130
|
$18.69 Million |
|
SRP Groupe SA
PA:SRP
|
$18.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INOVIQ LTD.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares INOVIQ LTD.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently INOVIQ LTD. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares INOVIQ LTD.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $12,943,265,089
- Average return on equity (ROE) among peers: -41.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INOVIQ LTD. (EGQ0) | €- | N/A | N/A | $18.70 Million |
| Spermosens AB (publ) (9R5) | $5.83 Million | -329.25% | 0.66x | $517.28K |
| BML Inc (BMZ) | $93.12 Billion | 14.72% | 0.49x | $462.01 Million |
| Genomic Vision Société Anonyme (G09) | $22.70 Million | -9.50% | 0.17x | $711.54K |
| ICON Public Limited Company (IJF) | $1.85 Billion | 17.96% | 0.86x | $6.44 Billion |
| Adicon Holdings Limited (K0U) | $1.83 Billion | 12.85% | 1.49x | $139.89 Million |
| WuXi XDC Cayman Inc. (L74) | $6.64 Billion | 16.11% | 0.37x | $2.05 Billion |
| NanoRepro AG (NN6) | $40.38 Million | -11.60% | 0.03x | $17.08 Million |
| PERRIGO (PGO) | $35.91 Million | -43.53% | 0.12x | $6.37K |